CDI Labs HuScan and VirScan
CDI Laboratories' Antygen Division, which provides contract research for R&D in the therapeutic and diagnostic space, has launched two biomarker discovery assays, HuScan and VirScan. HuScan detects antibodies against the entire human proteome via long peptides on the surface of bacteriophages, antibody pulldown, and sequencing readouts. VirScan detect antibodies against the proteomes of every viral strain known to infect humans in the same manner. Both assays represent the first commercial use of PhIP-seq technology, the company said.